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Abstract: The effects of gender differences and age on the treatment response to ﬂ  uvoxamine 
were investigated in major depressive Japanese patients. A total of 100 Japanese patients 
participated in this study. The daily dose of ﬂ  uvoxamine was ﬁ  xed to 100, 150 or 200 mg in the 
fourth week. This ﬁ  xed dose was maintained until the end of the 6-week study. The patients were 
divided into 3 groups: younger females, older females, and males. Depressive symptoms were 
evaluated using the Montgomery and Åsberg Depression Rating Scale (MADRS) at pretreatment 
and at 1, 2, 4, and 6 weeks after the commencement of the study. Seven of the 100 patients were 
excluded, and the remaining 93 patients constituted the subjects (50 females, 43 males). The 
number of intent-to-treat responders and non-responders was 55 and 38, respectively. There was 
a signiﬁ  cant difference in the changes in the time course of the MADRS score and changes in 
the MADRS scores at each evaluation point between the younger and older females. Younger 
females demonstrated a signiﬁ  cantly better response than older females. The results suggest that 
ﬂ  uvoxamine is more effective in younger female patients than in older female patients.
Keywords: major depressive disorder, ﬂ  uvoxamine, antidepressant response, menopausal 
status
Introduction
Selective serotonin reuptake inhibitors (SSRIs) are the most widely used drugs for the 
treatment of depression because their efﬁ  cacy is similar to that of tricyclic antidepres-
sants (TCAs); further, they have an advantage over TCAs for tolerability.1 Despite 
differences in structure and activity, SSRIs, including ﬂ  uvoxamine, share several 
common features, and there is no evidence for the superior efﬁ  cacy of one agent over 
another. In a review of double-blind comparative studies of ﬂ  uvoxamine vs imipramine 
for treating major depressive patients, no difference was indicated in 12 trials, while 
ﬂ  uvoxamine was found to be the superior antidepressant in 2 trials.2
Depression occurs more often in women than in men, and differences are also 
observed between men and women in terms of the clinical features of depression and 
response to treatments.3 Kornstein et al4 suggested that women had an advantage in 
terms of the response rate to sertraline, while men had a higher response rate to imip-
ramine. In this study, the responder analysis at the end point by menopausal status 
demonstrated that premenopausal women were signiﬁ  cantly more likely to respond 
to sertraline than imipramine, whereas the response rates to sertraline and imipramine 
of postmenopausal women were similar. However, Hildebrandt et al5 demonstrated 
similar clinical effects with antidepressant (clomipramine vs citalopram, paroxetine, 
and moclobemide) treatment for male and female patients with major and predomi-
nantly melancholic depression. There was also no gender difference in treatment 
response to sertraline in 6-month treatment of depression.6
In Japanese depressive patients, there was no signiﬁ  cant difference in treatment 
response to ﬂ  uvoxamine and paroxetine between males and females;7 however, we Neuropsychiatric Disease and Treatment 2009:5 152
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recently revealed that ﬂ  uvoxamine was more effective in 
younger female patients than in older female and male patients 
in a preliminary report dealing with 66 patients. A major 
limitation of this study was the small number of patients, 
particularly the number of younger females.8 Therefore, we 
recruited new patients in order to increase the total number of 
patients to 100. In the present study, we re-analyzed the effects 
of gender differences and age on the treatment response to 
ﬂ  uvoxamine in 100 major depressive patients.
Method
Subjects
This study included a total of 100 Japanese patients who 
fulﬁ  lled the Diagnostic and Statistical Manual of Mental 
Disorders (DSM)-IV criteria for the diagnosis of a major 
depressive disorder and whose Montgomery and Åsberg 
Depression Rating Scale (MADRS)9 scores at pretreat-
ment were 21 or higher. Patients suffering from other axis I 
disorders (such as dementia, substance abuse, dysthymia, 
panic disorder, obsessive-compulsive disorder, and gener-
alized anxiety disorder) and those with axis II disorders as 
determined by a clinical interview were excluded from the 
study. Patients with a past history of childhood disorders, and 
those with severe non-psychiatric medical disorders were also 
excluded. The subjects were patients aged between 20 and 
69 years who had not used any psychotropic drug for at least 
14 days before participating in the study. Informed consent 
was obtained from the subjects after providing them with a 
complete description of the study. Our study was performed 
in psychiatric units of general hospitals. Well trained psychia-
trists made diagnoses and provided antidepressant treatment 
for the patients.
Treatment
The same dose of ﬂ  uvoxamine was administered twice 
daily, after dinner and at bedtime, for 6 weeks. The initial 
daily dose was 50 mg, which was increased to 100 mg after 
1 week. After another week, the dose was set to 100, 150, or 
200 mg, depending on the clinical judgment of the treating 
psychiatrists; this ﬁ  xed dose was maintained until the end 
of the study. Patients with insomnia were prescribed 0.25 or 
0.5 mg of brotizolam, a benzodiazepine sedative hypnotic, 
at bedtime. No other psychotropic drugs were permitted 
during the study.
Data collection
The patients were divided into 3 groups: females aged  44 
years, females aged  44 years, and males. For the female 
patients, we set the cut-off point at 44 years of age because 
females aged  44 years have a high potential for the intact 
gonadotropin-releasing hormone (GnRH) pulse pattern and 
functioning ovulation cycle.10 The normal pattern of pulsatile 
GnRH secretion changes during the early 40s as a conse-
quence of irregularity in hypothalamic pacemaker function; 
therefore, both phases of the ovarian cycle are affected during 
the perimenopausal period.11,12 Several endocrine changes 
precede clinical menopause, such as changes in the pattern 
of pulsatile GnRH secretion;11 therefore, we used 44 years 
as the cut-off point to distinguish the fertile period from the 
peri-/postmenopausal periods. The severity of the depressive 
symptoms was assessed using MADRS. Assessments were 
conducted at the baseline and at 1, 2, 4, and 6 weeks after 
the initiation of ﬂ  uvoxamine treatment. A single person rated 
each patient. A decrease of 50% or higher in the baseline 
MADRS score was deﬁ  ned as a clinical response.
Statistical analysis
We used an intent-to-treat last-observation-carried-forward 
analysis. The clinical characteristics of the patients, responders, 
and non-responders were analyzed by a chi-square test or an 
unpaired t-test where appropriate. The distribution of respond-
ers and non-responders in the 3 groups was analyzed by a 
chi-square test. The changes in the time course of MADRS 
scores (the mean score at each evaluation point minus the mean 
score at the baseline) among females aged  44 years, females 
aged  44 years, and males were analyzed by a repeated-
measures analysis of variance (ANOVA). The changes in 
MADRS scores at 1, 2, 4, and 6 weeks among the 3 groups 
were analyzed by an unpaired t test. Statistical analysis was 
performed using StatView version 5.0 (SAS Institute INC., 
Cary, NC). All the tests were two-tailed, and a p value   0.05 
was regarded as signiﬁ  cant.
Results
Among the 100 patients, 3 stopped visiting our hospitals 
after the ﬁ  rst visit without providing an explanation. We 
excluded 4 patients from the current analysis because of poor 
compliance with pharmacotherapy. Therefore, the remaining 
93 patients constituted the subjects, who included 50 females 
and 43 males (mean age ± SD = 48.8 ± 13.7 years). The ﬁ  nal 
daily dose of ﬂ  uvoxamine was 50 mg for 7, 100 mg for 15, 
150 mg for 8, and 200 mg for 64 patients. Patient character-
istics are shown in Table 1.
The number of intent-to-treat responders and non-
responders was 55 and 38 patients, respectively. No sig-
niﬁ  cant difference was observed in average age, number Neuropsychiatric Disease and Treatment 2009:5 153
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of previous depressive episodes, proportion of melancholia 
and non-melancholia, and severity in MADRS scores at 
pretreatment between the responders and non-responders 
(Table 1). Table 2 shows the distributions and intent-to-
treat response rates to ﬂ  uvoxamine between responders and 
non-responders. Although the response rate of the females 
of age group  44 years was high (75%), there was no sig-
niﬁ  cant difference in the distributions of the responders and 
non-responders between females aged  44 years and those 
aged  44 years (χ2 = 2.79, p = 0.09), females aged  44 years 
and males (χ2 = 1.08, p = 0.30), and females aged  44 years 
and males (χ2 = 0.84, p = 0.36).
There was a signiﬁ  cant difference in the changes in 
the time course of the MADRS score between the females 
aged  44 years and those aged  44 years (F = 2.97, 
p = 0.02). However, there was no signiﬁ  cant difference 
between females aged  44 years and males (F = 1.50, 
p = 0.20), and females aged  44 years and males at 6 weeks 
(F = 0.96, p = 0.43) (Figure 1). Figure 2 depicts changes in 
the MADRS scores in the 3 groups. There was a signiﬁ  cant 
difference in the MADRS score at each evaluation point 
between females aged  44 years and those aged  44 years 
(1 week: t = –3.45, p = 0.001; 2 weeks: t = –2.71, p = 0.009; 
4 weeks: t = –2.11, p = 0.04; and 6 weeks: t = –2.17, p = 0.04). 
Although a signiﬁ  cant difference was observed between 
females aged  44 years and males for the MADRS scores in 
the ﬁ  rst week (t = 2.50, p = 0.015), there was no signiﬁ  cant 
difference at 2 weeks (t = 1.55, p = 0.13), 4 weeks (t = 1.12, 
p = 0.27), and 6 weeks (t = 1.11, P = 0.27). There was no 
signiﬁ  cant difference between females aged  44 years and 
males for the MADRS score at each evaluation point (1 week: 
t = –0.70, p = 0.49; 2 weeks: t = –0.47, p = 0.64; 4 weeks: 
t = –0.48, p = 0.63; and 6 weeks: t = –0.68, p = 0.50).
Discussion
The results of this study reveal that the ﬂ  uvoxamine treat-
ment signiﬁ  cantly improved the changes in the time course 
of MADRS score and changes in the MADRS scores at 
each evaluation point in younger female depressive patients 
(females aged  44 years) compared with older female 
patients (females aged  44 years). Our results were in agree-
ment with those of a recent study in which the menopause 
status negatively affected the SSRI treatment response of 
Caucasian female depressive patients treated in primary 
care.13 Kornstein et al4 hypothesized a mechanism for the 
effect of gender differences; the female gonadal hormones, 
particularly estrogen, may play an important role in antide-
pressant activity, thereby enhancing the response to SSRIs in 
younger women. Halbreich et al14 have shown that estrogen 
enhances monoaminergic activity and augments serotonin-
ergic postsynaptic responsiveness. Several studies have 
suggested that estrogen augments the response to SSRIs 
in female postmenopausal major depressive patients.15,16 
Therefore, we suggested that the augmentation therapy 
using estrogen was useful for postmenopausal patients who 
did not response to SSRIs. On the other hand, sex differ-
ences in depressive response during monoamine depletions 
in remitted depressive patients were recently reported. In the 
study, women experienced greater depressive responses than 
men during tryptophan depletion inducing hyposerotonengic 
Table 1 Clinical characteristics of the total patients, responders and non-responders in this study
Total
(N = 93)
Responders 
(N = 55)
Non-responders 
(N = 38) Analysis
Sex (male/female) 43/50 26/29 17/21 χ2 = 0.058 p = 0.81 n.sb
Age (year)a 48.8 ± 13.7 48.0 ± 13.6 50.0 ± 13.8 t = −0.69 p = 0.49 n.sc
Number of previous episodesa 0.43 ± 0.97 0.42 ± 1.13 0.45 ± 0.69 t = −0.14 p = 0.88 n.sc
Melancholia (yes/no) 36/57 19/36 17/21 χ2 = 0.98 p = 0.32 n.sb
Pretreatment total MADRS score 29.8 ± 5.2 29.5 ± 5.09 29.9 ± 5.33 t = −0.34 p = 0.73 n.sc
aData are expressed as mean ± SD
bAnalysis performed with the use of a chi-square test between the responders and non-responders.
cAnalysis performed with the use of an unpaired t-test between the responders and non-responders.
Table 2 Distribution of the responders and non-responders among females  44 years of age, females  44 years of age and males
  Total (N = 93) Female  44 (N = 16) Female  44 (N = 34) Male (N = 44)
Responder 55 (59.1%) 12 (75.0%) 17 (50.0%) 26 (60.5%)
Non-responder 38 (40.9%) 4 (25.0%) 17 (50.0%) 17 (39.5%)Neuropsychiatric Disease and Treatment 2009:5 154
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Figure 1 Changes in the time course of the MADRS scores in females aged  44 years, females aged  44 years, and males treated with ﬂ  uvoxamine. Each point represents 
the mean score ± SD. Analysis was performed using a repeated-measures analysis of variance (ANOVA).
*p   0.05.
Abbreviation: MADRS, Montgomery and Åsberg Depression Rating Scale.
**p < 0.01
n.s
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Figure 2 Changes in the MADRS scores in females aged  44 years, females aged  44 years, and males treated with ﬂ  uvoxamine at each evaluation point. Analysis was 
performed using an unpaired t test.
*p   0.05, **p   0.01.
Abbreviation: MADRS, Montgomery and Åsberg Depression Rating Scale.Neuropsychiatric Disease and Treatment 2009:5 155
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function, but not during catecholamine depletion.17 Similar 
results were obtained in another recent study on healthy 
people.18 These ﬁ  ndings suggest that differential sex effects 
in serotonengic function may be related to gender differences 
in the clinical effects of SSRIs.
In conclusion, the present study suggests that ﬂ  uvoxamine 
is more effective in younger female patients than in older 
female and male patients. The major limitation of this study 
is the lack of placebo control patients. A second limitation 
is the relatively small number of younger females. This 
limitation leads to the possibility of a false negative in the 
distributions of the responders and non-responders between 
younger females and older females.
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